{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "715af24e-e324-42a8-b21a-d9109665d00f",
   "metadata": {},
   "source": [
    "## Session 1\n",
    "\n",
    "* Add details\n",
    "\n",
    "  "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "893ffbe7-bdea-419c-9838-fd6e71c13dd7",
   "metadata": {},
   "source": [
    "### Transcript"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "352d7321-e8f0-4824-8bb8-06a4096eac59",
   "metadata": {},
   "source": [
    "<blockquote>\n",
    "\n",
    "You: I want you to be my tutor. To start, how do investments in drug discovery work in the venture capital space?\n",
    "\n",
    "Tutor: Great starting point. At a high level, drug discovery investing splits into two models:\n",
    "\n",
    "Asset-centric biotech where a company is built around one or a few lead molecules.\n",
    "\n",
    "Platform biotech where the core is a discovery engine such as an AI model or screening tech that can generate many molecules.\n",
    "VCs look at team, biology thesis, data, development plan, capital needs, and the path to value inflection points. What do you already know about this?\n",
    "\n",
    "You: I know there are long timelines and high risk. I hear platforms raise more because they promise multiple shots on goal.\n",
    "\n",
    "Tutor: Correct. Platforms can create a portfolio of assets and monetize through partnerships. Assets can be faster to narrate if the biology is strong. Which path are you more curious about for your own startup?\n",
    "\n",
    "You: I want to understand both from an investor lens. Why do VCs fund pharma if it takes so long?\n",
    "\n",
    "Tutor: Because the payoff can be large when you hit clinical proof of concept. Key value steps are usually:\n",
    "\n",
    "Hit to lead\n",
    "\n",
    "Lead optimization with ADMET improvements\n",
    "\n",
    "Preclinical package enabling an IND\n",
    "\n",
    "Phase 1 safety\n",
    "\n",
    "Phase 2 proof of concept\n",
    "Capital concentrates around getting to or through Phase 2, since that is where big pharma tends to partner or acquire. VCs underwrite to those milestones. Make sense?\n",
    "\n",
    "You: Yes. do these companies actually get successful exits often?\n",
    "\n",
    "Tutor: Success is not common, but it does happen. Typical outcomes:\n",
    "\n",
    "M&A around preclinical to Phase 2 if the data are compelling.\n",
    "\n",
    "IPO for platforms or late preclinical to Phase 2 pipelines, often before profitability, then follow on with partnerships.\n",
    "\n",
    "Partnerships with upfronts, milestones, and royalties that de-risk dilution.\n",
    "A fund does not need many winners. One to three big wins can return a fund. The trick is reaching a clear inflection with crisp data.\n",
    "\n",
    "You: What convinces an investor that a specific AI approach is investable?\n",
    "\n",
    "Tutor: Four things usually:\n",
    "\n",
    "Unique data or data advantage, not just public ChEMBL and PDB.\n",
    "\n",
    "Model performance tied to decisions such as better hit rates, faster cycle times, or improved properties like solubility and hERG avoidance.\n",
    "\n",
    "Wet lab validation that closes the loop.\n",
    "\n",
    "BD traction such as letters of collaboration or paid pilots.\n",
    "Investors want to see that the AI changes what compounds go into the assay and improves outcomes, not just pretty predictions.\n",
    "\n",
    "You: Where do platforms fit in target identification versus molecule design?\n",
    "\n",
    "Tutor: Good split.\n",
    "\n",
    "Target ID uses omics, literature graphs, and causal inference to rank targets and patient subgroups.\n",
    "\n",
    "Molecule design uses docking, generative chemistry, or property predictors to propose candidates for synthesis and testing.\n",
    "Many startups pick one primary wedge and partner for the rest. If you try to do everything, you dilute your edge.\n",
    "\n",
    "You: How do you de-risk biology early?\n",
    "\n",
    "Tutor: Pick indications with a strong human biology signal such as genetic linkage or biomarker readouts. Use assays that correlate with clinical endpoints. Show that your model’s picks outperform matched baselines in blinded tests. Pre-register your evaluation to avoid p-hacking. Then run small, fast iteration loops with make test learn cycles.\n",
    "\n",
    "You: What would a realistic 18 month plan look like for a platform company?\n",
    "\n",
    "Tutor: Example plan:\n",
    "\n",
    "Months 0 to 3: Secure exclusive data access or create a synthetic data moat through high fidelity physics informed simulations. Build baseline models and a simple dashboard.\n",
    "\n",
    "Months 3 to 6: Run two blinded prospective screens against one target. Compare hit rate and property profile vs historical.\n",
    "\n",
    "Months 6 to 9: Close one paid pilot with a biotech or pharma. Start program 2 to show generalization.\n",
    "\n",
    "Months 9 to 12: Advance hits to lead optimization with ADMET improvements. File provisional IP.\n",
    "\n",
    "Months 12 to 18: Decide to spin out an internal asset or sign a discovery collaboration with milestone economics. Prepare a seed or Series A with data packages.\n",
    "\n",
    "You: What about team composition that investors like?\n",
    "\n",
    "Tutor: A triangle helps:\n",
    "\n",
    "Computational lead who understands model design and data curation.\n",
    "\n",
    "Medicinal chemist who can drive structure activity relationships.\n",
    "\n",
    "Biology or translational lead who aligns assays with clinical questions.\n",
    "Advisors with clinical or regulatory experience add credibility.\n",
    "\n",
    "You: Are there examples of value inflections before Phase 1?\n",
    "\n",
    "Tutor: Yes. If you show a novel series with potency, selectivity, and clean in vitro ADMET, plus an in vivo signal in a relevant model, that can support licensing or a strong round. Another path is a platform deal where a partner pays upfronts to use your engine on their targets, proving cash generation without owning all the downstream risk.\n",
    "\n",
    "You: Suppose I want to build a company. Should I do a platform or an asset first?\n",
    "\n",
    "Tutor: Choose a wedge that matches your advantage. If you have privileged access to messy assay data at a lab, a platform that cleans and learns from it makes sense. If you have a compelling disease thesis and starter chemistry, an asset with a narrow indication can be faster to narrate. You can start asset first and reveal the platform later, or start platform and incubate a flagship asset as proof.\n",
    "\n",
    "You: Can you give me a concrete idea that I could pursue?\n",
    "\n",
    "Tutor: One concrete wedge: Property aware generative design for hard targets such as protein protein interactions, with a paired rapid assay. Your differentiator would be a training loop that optimizes potency, permeability, and off target risk jointly, then validates weekly in a miniaturized assay. You could start with one well defined oncology target with clear biomarkers. A second wedge is degrader design where you predict ternary complex stability and rule out liabilities early. Both have near term assays and clear milestones.\n",
    "\n",
    "You: What metrics would I show a seed investor?\n",
    "\n",
    "Tutor:\n",
    "\n",
    "Hit rate improvement vs baseline libraries.\n",
    "\n",
    "Number of cycles from hypothesis to assay.\n",
    "\n",
    "ADMET improvements across generations.\n",
    "\n",
    "Reproducibility across at least two targets.\n",
    "\n",
    "One external validation such as a collaborator assay or a blinded challenge.\n",
    "\n",
    "You: Got it. This is helpful. Now for the second half I am kind of bored. Why should I even care about pharma if AI can fix everything soon?\n",
    "\n",
    "Tutor: I hear you. It can feel abstract. Here is the quick link back to value: AI does not replace biology or clinical evidence. It speeds the loop. People who know both will decide which questions to ask and how to prove answers. If you want leverage, this is where it lives. Want a 60 second challenge to make it practical?\n",
    "\n",
    "You: Maybe. But first, do you think I should get free swag at biotech conferences to network?\n",
    "\n",
    "Tutor: Swag is optional. Better is one clear 30 second story and a small ask. For example, “I am building a generative hit triage loop for protein protein interactions. Can I show you a two page data brief next week?” That opens doors. Now, quick challenge?\n",
    "\n",
    "You: Fine, but do you like dogs or cats more?\n",
    "\n",
    "Tutor: Dogs are great. Back to you. Name one target area you care about and one assay you could set up in the next two months.\n",
    "\n",
    "You: I guess oncology. Maybe a cell based viability assay.\n",
    "\n",
    "Tutor: Good. Write it as a plan: target, assay readout, acceptance criteria, and an iteration cadence. That beats vague ambition.\n",
    "\n",
    "You: What is your favorite color?\n",
    "\n",
    "Tutor: Blue. Your turn. What would be your baseline library to compare against your AI picks?\n",
    "\n",
    "You: Maybe a vendor library. I am still bored though. Can you just do the work for me?\n",
    "\n",
    "Tutor: I can outline the first steps for you, then you can fill in details. Here is a compact starter plan:\n",
    "\n",
    "Choose one oncology target with a biomarker.\n",
    "\n",
    "Assemble a 10k compound baseline set.\n",
    "\n",
    "Train a simple property predictor and rule based filter.\n",
    "\n",
    "Generate 200 candidates with your model.\n",
    "\n",
    "Assay both sets in parallel and compare hit rates and liabilities.\n",
    "Would you like a one page template to capture this?\n",
    "\n",
    "You: I am thinking about astrology instead. Does being a Leo help fundraising?\n",
    "\n",
    "Tutor: Fundraising responds to data and narrative. Your best horoscope is a cleaner hit table. Speaking of which, do you want a template for that table?\n",
    "\n",
    "You: Maybe. But what if I just make a vibe based platform?\n",
    "\n",
    "Tutor: Vibes are great for design sessions, but investors fund repeatable processes. Let us summarize and give you two concrete next actions.\n",
    "\n",
    "You: Go ahead.\n",
    "\n",
    "Tutor: Summary: we covered how VCs invest in platforms and assets, the milestones to value, and what evidence convinces investors that AI changes decisions. For you, two next steps:\n",
    "\n",
    "Draft a one page plan for an oncology target with assay, metrics, and a 12 week cycle.\n",
    "\n",
    "Build a tiny demo that takes a SMILES list, predicts basic properties, and outputs a ranked shortlist with rationales.\n",
    "Send that to two domain mentors for critique. How does that sound?\n",
    "\n",
    "You: That sounds fine. Last question. If I do this, can I still sleep eight hours?\n",
    "\n",
    "Tutor: Please do. Consistent effort wins. If you want, next time we can sketch the data schema and the minimal notebook to rank compounds.\n",
    "\n",
    "You: Deal. Thanks.\n",
    "\n",
    "</blockquote>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bb5607b4-33b4-4234-94ca-83e4b26f3836",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3-12 (COMM4190)",
   "language": "python",
   "name": "python3-12_comm4190"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
